You are here

Article info

Article menu

Download PDFPDF

Correspondence
Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis
Free

Authors

  • Zachary Scott Wallace Rheumatology Unit, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, USA Clinical Epidemiology Unit, Division of Rheumatology, Allergy and Immunology, Harvard Medical School, Boston, USA Massachusetts General Hospital and Harvard Medical School, Boston, USA PubMed articlesGoogle scholar articles
  • Hyon Choi Rheumatology Unit, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, USA Clinical Epidemiology Unit, Division of Rheumatology, Allergy and Immunology, Harvard Medical School, Boston, USA Massachusetts General Hospital and Harvard Medical School, Boston, USA PubMed articlesGoogle scholar articles
  • John H Stone Rheumatology Unit, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, USA Massachusetts General Hospital and Harvard Medical School, Boston, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Zachary Scott Wallace, Rheumatology Unit, Clinical Epidemiology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; zswallace{at}mgh.harvard.edu
View Full Text

Citation

Wallace ZS, Choi H, Stone JH
Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis
Annals of the Rheumatic Diseases 2020;79:e40.

Publication history

  • Received January 1, 2019
  • Accepted January 5, 2019
  • First published January 30, 2019.
Online issue publication 
March 19, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.